Benjamin Maughan, MD
Basic profileThe University of Texas at San Antonio Health Science Center
Benjamin Maughan is an Oncology physician affiliated with The University of Texas at San Antonio Health Science Center. OpenAlex indexes 433 publications with 3,558 citations (h-index 31); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7979 Wurzbach Rd
San Antonio, TX 782294427
Telephone
210-450-1143Provider last certified this registry record 12 Mar 2026.
Clinical trials
- Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bayer Healthcare Pharmaceuticals Inc.Program year202518 payments$11,584openpaymentsdata.cms.gov ↗
- Eisai Inc.Program year20255 payments
- PFIZER INC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
55.2%Cytochrome P450 17A1 Inhibitor40.4%Abiraterone Acetate100%Part D≥52 patientsKinase inhibitor5%Cabometyx40%Everolimus36%Inlyta24%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
19.1%Corticosteroid12.5%Prednisone100%Part D≥35 patientsSerotonin-3 Receptor Antagonist3.7%Ondansetron Hcl61%Ondansetron Odt39%Part D<11 patients+ 1 more class in this area
Cardiovascular
18.1%Aldosterone antagonist (MRA)15.5%Eplerenone100%Part D≥27 patientsCalcium channel blocker2.5%Amlodipine Besylate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025
Journal of the National Comprehensive Cancer Network
2025 - Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study
Clinical Cancer Research
2024 - Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
Human Vaccines & Immunotherapeutics
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Stephen E. Harris
The University of Texas at San Antonio Health Science Center
Richard Tuli, MD, PhD
The University of Texas at San Antonio Health Science Center
Dean Kellogg, MD
The University of Texas at San Antonio Health Science Center
Marcos Restrepo, MD, MSc
The University of Texas at San Antonio Health Science Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”